nach oben

Archives of Dermatological Research

Erschienen in:

01.01.2013 | Original Paper

Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis

verfasst von: N. Eiró, C. Ovies, B. Fernandez-Garcia, C. C. Álvarez-Cuesta, L. González, L. O. González, F. J. Vizoso

Erschienen in: Archives of Dermatological Research | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival (p = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.

Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499–511. doi:10.1038/nri1391 PubMedCrossRef

Allhorn S, Boing C, Koch AA, Kimmig R, Gashaw I (2008) TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol 6:40. doi:10.1186/1477-7827-6-40 PubMedCrossRef

Armstrong BK, Kricker A (1994) Cutaneous melanoma. Cancer Surv 19–20:219–240PubMed

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/JCO.2009.23.4799 PubMedCrossRef

Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141. doi:S135961010100020X PubMedCrossRef

Bhattacharya D, Yusuf N (2012) Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012:716564. doi:10.1155/2012/716564 PubMed

Boring CC, Squires TS, Tong T (1993) Cancer statistics, 1993. CA Cancer J Clin 43(1):7–26PubMedCrossRef

Breslow A, Macht SD (1978) Evaluation of prognosis in stage I cutaneous melanoma. Plast Reconstr Surg 61(3):342–346PubMedCrossRef

Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, Bradding P (2005) The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 171(10):1103–1108. doi:10.1164/rccm.200409-1220OC PubMedCrossRef

10.

Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM, Albini A (2010) The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 8:112. doi:10.1186/1479-5876-8-112 PubMedCrossRef

11.

Cipponi A, Wieers G, van Baren N, Coulie PG (2011) Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60(8):1153–1160. doi:10.1007/s00262-011-1026-2 PubMedCrossRef

12.

Cochran AJ (1997) Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res 10(3):162–167PubMedCrossRef

13.

de Visser KE, Coussens LM (2005) The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54(11):1143–1152. doi:10.1007/s00262-005-0702-5 PubMedCrossRef

14.

Ermertcan AT, Ozturk F, Gunduz K (2011) Toll-like receptors and skin. J Eur Acad Dermatol Venereol 25(9):997–1006. doi:10.1111/j.1468-3083.2011.04049.x PubMedCrossRef

15.

Fang L, Lonsdorf AS, Hwang ST (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128(11):2596–2605. doi:10.1038/jid.2008.101 PubMedCrossRef

16.

Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133(6):1869–1881. doi:10.1053/j.gastro.2007.09.008 PubMedCrossRef

17.

Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, Escaff S, Vizoso FJ (2011) Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 60(2):217–226. doi:10.1007/s00262-010-0931-0 PubMedCrossRef

18.

Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10:665. doi:10.1186/1471-2407-10-665 PubMedCrossRef

19.

Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS (2008) Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 7(11):3642–3653. doi:10.1158/1535-7163.MCT-08-0582 PubMedCrossRef

20.

Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2):218–224. doi:10.1038/sj.onc.1210904 PubMedCrossRef

21.

Jin SH, Kang HY (2010) Activation of toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 22(4):486–489. doi:10.5021/ad.2010.22.4.486 PubMedCrossRef

22.

Kaiser WJ, Kaufman JL, Offermann MK (2004) IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J Immunol 172(3):1699–1710PubMed

23.

Kang HY, Park TJ, Jin SH (2009) Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol 129(1):243–246. doi:10.1038/jid.2008.184 PubMedCrossRef

24.

Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M (2000) Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 10(2):153–164PubMed

25.

Merrill RM, Feuer EJ (1996) Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 7(5):544–552PubMedCrossRef

26.

Meyer T, Stockfleth E, Christophers E (2007) Immune response profiles in human skin. Br J Dermatol 157(Suppl 2):1–7. doi:10.1111/j.1365-2133.2007.08264.x PubMedCrossRef

27.

Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29(13):2242–2252. doi:10.1038/emboj.2010.94 PubMedCrossRef

28.

Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:8CrossRef

29.

Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13(19):5703–5709. doi:10.1158/1078-0432.CCR-07-0603 PubMedCrossRef

30.

Moynagh PN (2005) TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 26(9):469–476. doi:10.1016/j.it.2005.06.009 PubMedCrossRef

31.

Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ (2007) Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 56(3):371–379. doi:10.1007/s00262-006-0193-z PubMedCrossRef

32.

O’Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61(2):177–197. doi:10.1124/pr.109.001073 PubMedCrossRef

33.

Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117(5):723–728. doi:10.1309/PEF8-GL6F-YWMC-AG56 PubMedCrossRef

34.

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78. doi:10.1038/nrc1256 PubMedCrossRef

35.

Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256(2):137–165. doi:10.1016/j.canlet.2007.05.013 PubMedCrossRef

36.

Saint-Jean M, Knol AC, Nguyen JM, Khammari A, Dreno B (2011) TLR expression in human melanoma cells. Eur J Dermatol 21(6):899–905. doi:10.1684/ejd.2011.1526 PubMed

37.

Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894–4901. doi:176/8/4894 PubMed

38.

Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13(15 Pt 1):4565–4574. doi:10.1158/1078-0432.CCR-07-0274 PubMedCrossRef

39.

Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR (2009) In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 69(18):7329–7337. doi:10.1158/0008-5472.CAN-09-0835 PubMedCrossRef

40.

Seki E, Brenner DA (2008) Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48(1):322–335. doi:10.1002/hep.22306 PubMedCrossRef

41.

Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 69(22):8710–8717. doi:10.1158/0008-5472.CAN-09-1602 PubMedCrossRef

42.

Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH (2002) CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99(7):2468–2476PubMedCrossRef

43.

Swerlick RA, Chen S (1997) The melanoma epidemic: more apparent than real? Mayo Clin Proc 72(6):559–564PubMedCrossRef

44.

Valins W, Amini S, Berman B (2010) The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol 3(9):20–29

Titel: Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis
verfasst von: N. Eiró
C. Ovies
B. Fernandez-Garcia
C. C. Álvarez-Cuesta
L. González
L. O. González
F. J. Vizoso
Publikationsdatum: 01.01.2013
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 1/2013
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-012-1300-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis

Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial–mesenchymal transition in squamous cell carcinoma

Effects of Cervi cornus Colla (deer antler glue) in the reconstruction of a skin equivalent model

Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis

Chemoprevention of doxorubicin-induced alopecia in mice by dietary administration of l-cystine and vitamin B6